Axogen (AXGN) announced that the FDA has approved the biologics license application for Avance. Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged one month or older with sensory, mixed, and motor peripheral nerve discontinuities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen Secures FDA Approval for Avance Nerve Scaffold
- AxoGen initiated with an Outperform at Mizuho
- AxoGen price target raised to $26 from $25 at H.C. Wainwright
- AxoGen’s Strong Financial Performance and Strategic Advancements Justify Buy Rating
- AxoGen’s Strong Market Position and Growth Potential Justify Buy Rating